-
1 Comment
Hancock Jaffe Laboratories, Inc is currently in a long term downtrend where the price is trading 6.1% below its 200 day moving average.
From a valuation standpoint, the stock is 83.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 216.9.
Hancock Jaffe Laboratories, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 90.9% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 61.4% to $-3M since the same quarter in the previous year.
Based on the above factors, Hancock Jaffe Laboratories, Inc gets an overall score of 1/5.
Sector | Healthcare |
---|---|
Industry | Medical Devices |
Exchange | NASDAQ |
CurrencyCode | USD |
ISIN | US29415J1060 |
PE Ratio | None |
---|---|
Market Cap | 98M |
Target Price | 26 |
Dividend Yield | 0.0% |
Beta | 1.54 |
Hancock Jaffe Laboratories, Inc., a medical device company, develops and sells tissue-based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It engages in the development and manufacture of bioprosthetic medical devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency; and the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries. The company was founded in 1987 and is headquartered in Irvine, California. Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for HJLI using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025